4.5 Review

Managing Suicide Risk in Patients with Schizophrenia

期刊

CNS DRUGS
卷 25, 期 2, 页码 129-143

出版社

ADIS INT LTD
DOI: 10.2165/11586450-000000000-00000

关键词

-

资金

  1. VISN 4 CPPF
  2. American Foundation for Suicide Prevention
  3. VISN 4 and VISN 22 MIRECC
  4. University of California, San Diego Center for Community
  5. Aspect Medical and PamLab
  6. Forest
  7. AstraZeneca
  8. Bristol Meyers Squibb
  9. Pfizer
  10. Johnson Johnson
  11. Solvay
  12. Eli Lilly
  13. [MH6398]
  14. NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063798, R01MH063931] Funding Source: NIH RePORTER

向作者/读者索取更多资源

The management of suicide risk in patients with schizophrenia poses many challenges for clinicians. Compared with the general population, these patients have an 8.5-fold greater risk of suicide. This article reviews the literature dealing with the treatment of at-risk patients with schizophrenia. An integrated psychosocial and pharmacological approach to managing this population of patients is recommended. Although there is at least modest evidence suggesting that antipsychotic medications protect against suicidal risk, the evidence appears to be most favourable for second-generation anti-psychotics, particularly clozapine, which is the only medication approved by the US FDA for preventing suicide in patients with schizophrenia. In addition, treating depressive symptoms in patients with schizophrenia is an important component of suicide risk reduction. While selective serotonin receptor inhibitors (SSRIs) ameliorate depressive symptoms in patients with schizophrenia, they also appear to attenuate suicidal thoughts. Further research is needed to more effectively personalize the treatment of suicidal thoughts and behaviours and the prevention of suicide in patients with schizophrenia.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据